株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

末梢血管ステント:医療機器のパイプライン評価

Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017

発行 GlobalData 商品コード 223329
出版日 ページ情報 英文 246 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
末梢血管ステント:医療機器のパイプライン評価 Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017
出版日: 2017年10月01日 ページ情報: 英文 246 Pages
概要

当レポートでは、世界の末梢血管ステント市場における、主要なパイプライン製品 (医療機器) とその治験の進行状況について調査すると共に、製品特性の比較分析 (治験の進行段階別) や、主要企業のプロファイルおよび代表的製品、昨今の市場動静 (資本取引・事業提携など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 末梢血管ステントの概要

第3章 現在治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:セグメント別
  • パイプライン製品:領域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 末梢血管ステント心臓:各企業で現在治験中のパイプライン製品

  • 末梢血管ステントの企業:治験段階別のパイプライン製品
  • 末梢血管ステント:治験段階別のパイプライン製品

第5章 末梢血管ステントの企業・製品の概要

  • 3D Biotek LLC
  • 480 Biomedical In
  • Abbott Vascular Inc.
  • Biotronik SE & Co KG
  • Boston Scientific Corp
  • C. R. Bard Inc
  • Cardiatis SA
  • Cook Medical Inc
  • Cordis Corp
  • Corinnova Inc
  • Cytograft Tissue Engineering Inc
  • Efferent Labs Inc
  • Electroformed Stents Inc
  • Elixir Medical Corp
  • Hexacath
  • InspireMD Inc
  • Intact Vascular, LLC
  • Lifetech Scientific (Shenzhen) Co., Ltd
  • LimFlow GmbH
  • Medinol Ltd
  • Medtronic plc
  • MicroVention, Inc.
  • Natec Medical Ltd
  • Nexeon MedSystems Inc
  • ニプロ
  • Northwestern University
  • NSVascular, Inc.
  • PeriTec Biosciences Ltd
  • Stron Medical
  • Synergy Flow Ltd
  • Taewoong Medical Co.,Ltd.
  • Tepha Inc
  • TissueGen Inc
  • University of Michigan
  • University of Texas Medical Branch at Galveston
  • Vascular Bioresorbable Technologies
  • Vascular Concepts Ltd
  • Veniti Inc
  • Veryan Medical Limited
  • VueKlar Cardiovascular Ltd
  • Xenogenics Corporation

第6章 末梢血管ステント市場:昨今の動向 (全77件)

第7章 提言

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0467EPD

GlobalData's Medical Devices sector report, "Peripheral Vascular Stents - Medical Devices Pipeline Assessment, 2017" provides an overview of Peripheral Vascular Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Vascular Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Peripheral Vascular Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Peripheral Vascular Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Peripheral Vascular Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Peripheral Vascular Stents Overview 12

3 Products under Development 13

  • 3.1 Peripheral Vascular Stents - Pipeline Products by Stage of Development 13
  • 3.2 Peripheral Vascular Stents - Pipeline Products by Segment 14
  • 3.3 Peripheral Vascular Stents - Pipeline Products by Territory 15
  • 3.4 Peripheral Vascular Stents - Pipeline Products by Regulatory Path 16
  • 3.5 Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 17
  • 3.6 Peripheral Vascular Stents - Ongoing Clinical Trials 18

4 Peripheral Vascular Stents - Pipeline Products under Development by Companies 19

  • 4.1 Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development 19
  • 4.2 Peripheral Vascular Stents - Pipeline Products by Stage of Development 21

5 Peripheral Vascular Stents Companies and Product Overview 24

  • 5.1 3D Biotek LLC Company Overview 24
  • 5.2 480 Biomedical Inc Company Overview 25
  • 5.3 Abbott Vascular Inc Company Overview 29
  • 5.4 AndraTec GmbH Company Overview 32
  • 5.5 Biotronik SE & Co KG Company Overview 33
  • 5.6 Boston Scientific Corp Company Overview 37
  • 5.7 C. R. Bard Inc Company Overview 43
  • 5.8 Cardiatis SA Company Overview 47
  • 5.9 Cook Medical Inc Company Overview 48
  • 5.10 Cordis Corp Company Overview 58
  • 5.11 Corinnova Inc Company Overview 64
  • 5.12 Cytograft Tissue Engineering Inc (Inactive) Company Overview 65
  • 5.13 Efferent Labs Inc Company Overview 66
  • 5.14 Electroformed Stents Inc Company Overview 67
  • 5.15 Elixir Medical Corp Company Overview 69
  • 5.16 Hexacath SA Company Overview 72
  • 5.17 InspireMD Inc Company Overview 73
  • 5.18 Intact Vascular LLC Company Overview 74
  • 5.19 iVascular SLU Company Overview 79
  • 5.20 Lifetech Scientific (Shenzhen) Co Ltd Company Overview 80
  • 5.21 LimFlow GmbH Company Overview 82
  • 5.22 Medinol Ltd Company Overview 85
  • 5.23 Micell Technologies Inc Company Overview 86
  • 5.24 MicroVention Inc Company Overview 87
  • 5.25 Natec Medical Ltd Company Overview 88
  • 5.26 Nexeon MedSystems Inc Company Overview 89
  • 5.27 Nipro Corp Company Overview 90
  • 5.28 Northwestern University Company Overview 91
  • 5.29 NSVascular, Inc. Company Overview 92
  • 5.30 PeriTec Biosciences Ltd Company Overview 93
  • 5.31 QualiMed Innovative Medizinprodukte GmbH Company Overview 95
  • 5.32 Qvanteq AG Company Overview 98
  • 5.33 REVA Medical Inc Company Overview 99
  • 5.34 Stron Medical Company Overview 100
  • 5.35 Synergy Flow Ltd Company Overview 101
  • 5.36 Taewoong Medical Co Ltd Company Overview 102
  • 5.37 Tepha Inc Company Overview 110
  • 5.38 TissueGen Inc Company Overview 111
  • 5.39 University of Michigan Company Overview 112
  • 5.40 University of Pittsburgh Medical Center Company Overview 113
  • 5.41 Vascular Bioresorbable Technologies Company Overview 114
  • 5.42 Vascular Concepts Ltd Company Overview 116
  • 5.43 Vascular Dynamics Ltd. Company Overview 119
  • 5.44 Veniti Inc Company Overview 123
  • 5.45 Veryan Medical Ltd Company Overview 126
  • 5.46 VueKlar Cardiovascular Ltd Company Overview 130
  • 5.47 Wake Forest University Health Sciences Company Overview 132
  • 5.48 Xenogenics Corporation Company Overview 133

6 Peripheral Vascular Stents- Recent Developments 135

  • 6.1 Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index 135
  • 6.2 Sep 01, 2017: Data Published in The Lancet Shows Positive Results at Primary Endpoint in the Treatment of Resistant Hypertension with MobiusHD Device 135
  • 6.3 Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices 136
  • 6.4 Aug 28, 2017: Interim Data on MobiusHD Presented at the European Society of Cardiology Shows Promise in the Treatment of Resistant Hypertension 138
  • 6.5 Aug 22, 2017: Vascular Dynamics, a Part of the Rainbow Medical Investment Cluster, Received FDA Approval to Begin Conclusive and Pivotal Trial Experimentation for Their Flagship Product Designed to Treat Chronic Hypertension 138
  • 6.6 Aug 22, 2017: Getinge announces full U.S. availability of Pulsar-18 self-expanding stent from BIOTRONIK for patients with peripheral artery disease 139
  • 6.7 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 140
  • 6.8 Aug 15, 2017: Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD System for the Treatment of Resistant Hypertension 143
  • 6.9 Aug 10, 2017: Neovasc Announces Results for the Second Quarter of 2017 143
  • 6.10 Aug 08, 2017: Inspire Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017 147
  • 6.11 Aug 08, 2017: InspireMD Reports Double Digit Sequential and Year-Over-Year Revenue Growth for the Second Quarter of 2017 148
  • 6.12 Aug 01, 2017: LimFlow Announces Publication of Positive Results from Pilot Study of LimFlow Percutaneous Deep Vein Arterialization (pDVA) System 149
  • 6.13 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 150
  • 6.14 Jul 26, 2017: Merit Medical Reports Record Revenue and Non-GAAP Net Income for Second Quarter 2017, Raises 2017 Guidance and Gives Preliminary 2018-2019 Guidance 152
  • 6.15 Jul 26, 2017: CONMED Announces Second Quarter 2017 Financial Results 153
  • 6.16 Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 154
  • 6.17 Jul 18, 2017: Intact Vascular Announces Enrollment of First European Patient in Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial with the Tack Endovascular System 156
  • 6.18 Jul 18, 2017: AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results 157
  • 6.19 Jul 12, 2017: STENTYS: Revenues Of €1.7 Million in the Second Quarter Of 2017 159
  • 6.20 Jul 11, 2017: LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study 160
  • 6.21 Jul 10, 2017: FDA Approves 6-Month Primary Endpoint for the Tack Endovascular System in Below the Knee Disease 160
  • 6.22 Jul 03, 2017: BIOTRONIK US Announces Pivotal Trial Results of the Pulsar-18 Stent with 4-French Delivery System 161
  • 6.23 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 162
  • 6.24 Jun 06, 2017: LimFlow Expands Senior Management Team and Opens Silicon Valley Office 164
  • 6.25 Jun 02, 2017: InspireMD Announces Appointment of Paul Stuka as Chairman of the Board 165
  • 6.26 May 26, 2017: Merit Medical Announces Appointment of New Director 165
  • 6.27 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 166
  • 6.28 May 15, 2017: Elixir Medical To Present Data on PRAVA Bioresorbable scaffold system at EuroPCR 2017 169
  • 6.29 May 10, 2017: Neovasc Announces Results for the First Quarter of 2017 169
  • 6.30 Apr 27, 2017: New Data Show Efficacy of Pulsar-18 Bare Metal Stent; Combination with Passeo-18 Lux DCB Challenges Results with Drug-Eluting Stents 171
  • 6.31 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 172
  • 6.32 Apr 27, 2017: Merit Medical Reports Results for First Quarter of 2017 173
  • 6.33 Apr 26, 2017: LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in "No Option" Critical Limb Ischemia Patients 174
  • 6.34 Apr 26, 2017: CONMED Announces First Quarter 2017 Financial Results 175
  • 6.35 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results 176
  • 6.36 Apr 24, 2017: STENTYS Reports a 22% Increase in Revenues in the First Quarter of 2017 177
  • 6.37 Apr 23, 2017: Bard Announces First Quarter Results 178
  • 6.38 Apr 21, 2017: Getinge launches the new Advanta V12 - 32mm Balloon Expandable Covered Stent 179
  • 6.39 Apr 20, 2017: Lombard Medical Appoints New CEO 179
  • 6.40 Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 179
  • 6.41 Apr 03, 2017: iVascular Receives CE Mark Approval for iVolution 200mm SX stent 182
  • 6.42 Apr 03, 2017: STENTYS is Strengthening Its Board by Co-Opting Two New Independent Members 182
  • 6.43 Mar 30, 2017: AngioDynamics Reports Fiscal 2017 Third Quarter Results 183
  • 6.44 Mar 24, 2017: LifeTech Announces 2016 Annual Results 184
  • 6.45 Mar 23, 2017: Intact Vascular Announces Completion Of Enrollment In The Tack Optimized Balloon Angioplasty II (Toba II) Clinical Trial 186
  • 6.46 Mar 23, 2017: Neovasc Announces Results for the Fourth Quarter and Fiscal Year 2016 187
  • 6.47 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech 190
  • 6.48 Mar 10, 2017: Neovasc Announces TSX Symbol Change to NVCN 191
  • 6.49 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia 191
  • 6.50 Mar 06, 2017: GORE TIGRIS Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease 192
  • 6.51 Mar 02, 2017: North Dallas Research Associates and Cardiac Center of Texas Begin Enrollment in TOBA II BTK Clinical Trial for New Peripheral Revascularization Treatment Option 193
  • 6.52 Feb 27, 2017: TissueGen appoints new scientific advisory board member 193
  • 6.53 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 194
  • 6.54 Feb 21, 2017: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2016 197
  • 6.55 Feb 16, 2017: Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US 198
  • 6.56 Feb 16, 2017: InspireMD Provides Year End Business Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 198
  • 6.57 Feb 13, 2017: Intact Vascular's Tack Optimized Balloon Angioplasty II Below The Knee (TOBA II BTK) Clinical Trial Commences Enrollment With First Implant Of The Tack Endovascular System 200
  • 6.58 Feb 09, 2017: Terumo Announces Change of Executive Officers 200
  • 6.59 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 202
  • 6.60 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 202
  • 6.61 Feb 01, 2017: Vascular Dynamics' Announces Expedited Access Pathway Designation by FDA for MobiusHD to Accelerate US Access for Treatment of Resistant Hypertension 204
  • 6.62 Feb 01, 2017: CONMED Announces Fourth Quarter and Fiscal Year 2016 Financial Results 205
  • 6.63 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 206
  • 6.64 Jan 31, 2017: Terumo Opens a Branch in Yangon 208
  • 6.65 Jan 30, 2017: FDA Approves First Balloon Expandable Stent Graft For Use In The Iliac Artery 208
  • 6.66 Jan 26, 2017: Bard Announces Fourth Quarter Results 209
  • 6.67 Jan 18, 2017: Neovasc Announces Update in Litigation with CardiAQ 210
  • 6.68 Jan 17, 2017: Intact Vascular's Tack Endovascular System Secures CE Mark for Repair of Dissections Following Angioplasty Below the Knee 210
  • 6.69 Jan 12, 2017: STENTYS: 2016 Annual Revenues up 20% at €7.3 Million 211
  • 6.70 Jan 06, 2017: AngioDynamics Reports Fiscal 2017 Second Quarter Results 211
  • 6.71 Dec 12, 2016: Terumo Formulates 5-Year Mid- to Long-term Growth Strategy 213
  • 6.72 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 213
  • 6.73 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 215
  • 6.74 Nov 21, 2016: VEITHsymposium 2016: BIOTRONIK Showcases Positive Results for Pulsar-18 Stent in the SFA 218
  • 6.75 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 219
  • 6.76 Nov 15, 2016: Final Patient Enrolled for Iliofemoral Venous Stent Study 219
  • 6.77 Nov 15, 2016: LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia Technology Designed to Restore Perfusion for "No Option" Patients 220
  • 6.78 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 220
  • 6.79 Nov 14, 2016: InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016 221
  • 6.80 Nov 14, 2016: Neovasc Reports Third Quarter Results for 2016 223
  • 6.81 Nov 09, 2016: AngioDynamics Announces Addition of New Board Members 226
  • 6.82 Oct 31, 2016: FDA Approves TOBA II BTK Pivotal IDE Clinical Study 226
  • 6.83 Oct 27, 2016: CONMED Announces Third Quarter 2016 Financial Results 227
  • 6.84 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 228
  • 6.85 Oct 26, 2016: Merit Medical Reports Sales Up 15.3% for the Quarter Ended September 30, 2016 230
  • 6.86 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 231
  • 6.87 Oct 25, 2016: Bard Announces Third Quarter Results 233
  • 6.88 Oct 24, 2016: Boston Scientific announced key Presentations on Eluvia Drug-Eluting Vascular Stent System at Transcatheter Cardiovascular Therapeutics 2016 233
  • 6.89 Oct 20, 2016: Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease 234
  • 6.90 Oct 19, 2016: Abbott Reports Third-Quarter 2016 Results 235
  • 6.91 Oct 18, 2016: LimFlow Names Daniel Rose as Chief Executive Officer 237
  • 6.92 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 238
  • 6.93 Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results 239
  • 6.94 Sep 30, 2016: Pitt Team Receives $2.5 million in DOD Funds for First Retrievable Vascular Stent 240
  • 6.95 Sep 30, 2016: Pitt Team Receives $2.5 million in DOD Funds for First Retrievable Vascular Stent 241

7 Appendix 242

  • 7.1 Methodology 242
  • 7.2 About GlobalData 245
  • 7.3 Contact Us 245
  • 7.4 Disclaimer 245

List of Tables

1.1 List of Tables

  • Table 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development 14
  • Table 2: Peripheral Vascular Stents - Pipeline Products by Segment 15
  • Table 3: Peripheral Vascular Stents - Pipeline Products by Territory 16
  • Table 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path 17
  • Table 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 18
  • Table 6: Peripheral Vascular Stents - Ongoing Clinical Trials 19
  • Table 7: Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development 20
  • Table 8: Peripheral Vascular Stents - Pipeline Products by Stage of Development 22
  • Table 9: 3D Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 10: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Status 25
  • Table 11: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Description 25
  • Table 12: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 13: Stanza Bioresorbable Pediatric Scaffold - Product Status 26
  • Table 14: Stanza Bioresorbable Pediatric Scaffold - Product Description 26
  • Table 15: Stanza Bioresorbable Self-Expanding Scaffold - Product Status 27
  • Table 16: Stanza Bioresorbable Self-Expanding Scaffold - Product Description 27
  • Table 17: 480 Biomedical Inc - Ongoing Clinical Trials Overview 28
  • Table 18: Stanza Bioresorbable Self-Expanding Scaffold - An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions 29
  • Table 19: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 20: ESPRIT Bioresorbable Vascular Scaffold - Product Status 30
  • Table 21: ESPRIT Bioresorbable Vascular Scaffold - Product Description 30
  • Table 22: Abbott Vascular Inc - Ongoing Clinical Trials Overview 31
  • Table 23: ESPRIT Bioresorbable Vascular Scaffold - Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis 32
  • Table 24: ESPRIT Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB) 32
  • Table 25: AndraTec GmbH Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 26: Pillar Bifurcation Reconstruction Device - Product Status 33
  • Table 27: Pillar Bifurcation Reconstruction Device - Product Description 33
  • Table 28: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 29: Astron Pulsar Self Expanding Peripheral Stent - Product Status 34
  • Table 30: Astron Pulsar Self Expanding Peripheral Stent - Product Description 35
  • Table 31: Biotronik SE & Co KG - Ongoing Clinical Trials Overview 36
  • Table 32: Astron Pulsar Self Expanding Peripheral Stent - BIOTRONIK - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents: BIOFLEX-I Europe 37
  • Table 33: Astron Pulsar Self Expanding Peripheral Stent - Self-expanding Nitinol Stents of High Versus Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions 37
  • Table 34: Astron Pulsar Self Expanding Peripheral Stent - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents 37
  • Table 35: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 36: Eluvia Drug-Eluting Vascular Stent System - Product Status 38
  • Table 37: Eluvia Drug-Eluting Vascular Stent System - Product Description 39
  • Table 38: Gallbladder Drainage System - Product Status 39
  • Table 39: Gallbladder Drainage System - Product Description 39
  • Table 40: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Status 40
  • Table 41: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Description 40
  • Table 42: Boston Scientific Corp - Ongoing Clinical Trials Overview 41
  • Table 43: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 42
  • Table 44: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 42
  • Table 45: Eluvia Drug-Eluting Vascular Stent System - A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-comers with Superficial Femoral Artery and Proximal Popliteal Artery Disease 42
  • Table 46: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Sinai Vein Stent Registry 43
  • Table 47: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 48: Bard LifeStent 5F Vascular Stent System - Product Status 44
  • Table 49: Bard LifeStent 5F Vascular Stent System - Product Description 45
  • Table 50: VENOVO Venous Stent - Product Status 45
  • Table 51: VENOVO Venous Stent - Product Description 45
  • Table 52: C. R. Bard Inc - Ongoing Clinical Trials Overview 46
  • Table 53: Bard LifeStent 5F Vascular Stent System - A Prospective Study of the Performance of the Bard Lifestent 5F Vascular Stent System 47
  • Table 54: Cardiatis SA Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 55: Cardiatis FluidSmart 3D Stent - Product Status 48
  • Table 56: Cardiatis FluidSmart 3D Stent - Product Description 48
  • Table 57: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 58: Evolution Biliary Stent System-Partially Covered - Product Status 49
  • Table 59: Evolution Biliary Stent System-Partially Covered - Product Description 49
  • Table 60: Evolution Esophageal Stent System-Fully Covered - Product Status 50
  • Table 61: Evolution Esophageal Stent System-Fully Covered - Product Description 50
  • Table 62: Zenith Connection Endovascular Covered Stent - Product Status 50
  • Table 63: Zenith Connection Endovascular Covered Stent - Product Description 51
  • Table 64: ZILVER PTX Drug Eluting Peripheral Stent - Product Status 51
  • Table 65: ZILVER PTX Drug Eluting Peripheral Stent - Product Description 51
  • Table 66: Zilver Vena Venous Self-Expanding Stent - Product Status 52
  • Table 67: Zilver Vena Venous Self-Expanding Stent - Product Description 52
  • Table 68: Cook Medical Inc - Ongoing Clinical Trials Overview 53
  • Table 69: ZILVER PTX Drug Eluting Peripheral Stent - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries 54
  • Table 70: ZILVER PTX Drug Eluting Peripheral Stent - Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions 54
  • Table 71: ZILVER PTX Drug Eluting Peripheral Stent - Comparison of the Primary Long Versus Short Coverage with Drug-Eluting Stents for Long Femoropopliteal Artery Disease (PARADE II): Investigator-initiated Clinical Study 54
  • Table 72: ZILVER PTX Drug Eluting Peripheral Stent - Drug Eluting Stent for the Management of Peripheral Arterial Disease of the SFA (DESPERADO-SFA Study) 55
  • Table 73: ZILVER PTX Drug Eluting Peripheral Stent - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses 55
  • Table 74: ZILVER PTX Drug Eluting Peripheral Stent - The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment the Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions (ZILVERPASS) 55
  • Table 75: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Drug-eluting Peripheral Stent Post-approval Study 56
  • Table 76: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Post-market Surveillance Study of Paclitaxel-eluting Stents for Treating Femoropopliteal Artery Disease in Japan 56
  • Table 77: Zilver Vena Venous Self-Expanding Stent - Evaluation of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction 57
  • Table 78: Evolution Esophageal Stent System-Fully Covered - Clinical Investigation to Evaluate Removal of the Evolution Esophageal Stent - Fully Covered 58
  • Table 79: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 80: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status 59
  • Table 81: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description 60
  • Table 82: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status 60
  • Table 83: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description 60
  • Table 84: FlexStent Self Expanding Venous Stent System - Product Status 61
  • Table 85: FlexStent Self Expanding Venous Stent System - Product Description 61
  • Table 86: Tibial SE FlexStent - Product Status 61
  • Table 87: Tibial SE FlexStent - Product Description 62
  • Table 88: Cordis Corp - Ongoing Clinical Trials Overview 63
  • Table 89: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study 64
  • Table 90: Corinnova Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 91: Hybrid Dynamic Stent - Product Status 65
  • Table 92: Hybrid Dynamic Stent - Product Description 65
  • Table 93: Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 94: LifeJacket Stent Graft - Peripheral - Product Status 66
  • Table 95: LifeJacket Stent Graft - Peripheral - Product Description 66
  • Table 96: Efferent Labs Inc Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 97: RTI-LICD Plexisense - Product Status 67
  • Table 98: RTI-LICD Plexisense - Product Description 67
  • Table 99: Electroformed Stents Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 100: Helical Stent - Product Status 68
  • Table 101: Helical Stent - Product Description 68
  • Table 102: Patch Stent - Product Status 69
  • Table 103: Patch Stent - Product Description 69
  • Table 104: Pleated Stent - Product Status 69
  • Table 105: Pleated Stent - Product Description 69
  • Table 106: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 107: PRAVA Bioresorbable Scaffold - Product Status 70
  • Table 108: PRAVA Bioresorbable Scaffold - Product Description 70
  • Table 109: Elixir Medical Corp - Ongoing Clinical Trials Overview 71
  • Table 110: PRAVA Bioresorbable Scaffold - Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization: DESappear Study 72
  • Table 111: Hexacath SA Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 112: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Status 73
  • Table 113: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Description 73
  • Table 114: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 115: PVGuard Peripheral - Product Status 74
  • Table 116: PVGuard Peripheral - Product Description 74
  • Table 117: Intact Vascular LLC Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 118: Tack Endovascular System - ATK - Product Status 75
  • Table 119: Tack Endovascular System - ATK - Product Description 75
  • Table 120: Tack Endovascular System - BTK - Product Status 76
  • Table 121: Tack Endovascular System - BTK - Product Description 76
  • Table 122: Intact Vascular LLC - Ongoing Clinical Trials Overview 77
  • Table 123: Tack Endovascular System - ATK - Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler 78
  • Table 124: Tack Endovascular System - ATK - Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System 78
  • Table 125: Tack Endovascular System - ATK - Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System 78
  • Table 126: Tack Endovascular System - BTK - Tack Optimized Balloon Angioplasty Study for the below the Knee Arteries Using the Tack Endovascular System 79
  • Table 127: iVascular SLU Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 128: Angiolite - BTK - Product Status 80
  • Table 129: Angiolite - BTK - Product Description 80
  • Table 130: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 131: Peripheral Bare Stent - Product Status 81
  • Table 132: Peripheral Bare Stent - Product Description 81
  • Table 133: Peripheral Cover Stent - Product Status 82
  • Table 134: Peripheral Cover Stent - Product Description 82
  • Table 135: LimFlow GmbH Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 136: LimFlow Percutaneous Deep Vein Arterialisation System - Product Status 83
  • Table 137: LimFlow Percutaneous Deep Vein Arterialisation System - Product Description 83
  • Table 138: LimFlow GmbH - Ongoing Clinical Trials Overview 84

List of Figures

1.2 List of Figures

  • Figure 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development 14
  • Figure 2: Peripheral Vascular Stents - Pipeline Products by Segment 15
  • Figure 3: Peripheral Vascular Stents - Pipeline Products by Territory 16
  • Figure 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path 17
  • Figure 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date 18
  • Figure 6: Peripheral Vascular Stents - Ongoing Clinical Trials 19
Back to Top